Streamlining Toujeo Prior Authorization for Dermatology Practices

The Landscape of Prior Authorization in Dermatology

Prior authorization (PA) remains a significant administrative challenge across healthcare, particularly in specialties like dermatology where high-cost biologics and specialized procedures are common. Dermatology PA concentrates heavily on categories such as biologics for psoriasis, eczema, and hidradenitis suppurativa, as well as Mohs micrographic surgery. Managing these specific PAs efficiently is critical for patient access and revenue cycle health.

Navigating Prior Authorization for High-Volume Medications

While Toujeo is a high-volume PA target across various commercial, Medicare Advantage, and Medicaid managed care plans, its management within a dermatology practice often involves co-morbid conditions. The operational challenge lies in efficiently processing PAs for all medications, including those prescribed by other specialists, alongside the dermatology-specific treatment PAs. Klivira's platform provides the necessary tools to manage this diverse PA workload, ensuring consistent and compliant submissions.

Key Dermatology Prior Authorization Categories and Documentation Needs

• **Biologics for psoriasis and psoriatic arthritis:** Requires diagnosis (PASI/BSA), prior topical/phototherapy/conventional systemic therapy trials, TB/hepatitis screening, step therapy compliance based on AAD Clinical Guidelines.
• **Biologics for atopic dermatitis:** Requires diagnosis criteria, EASI/SCORAD severity documentation, topical therapy trial, and age-appropriate indications.
• **Hidradenitis suppurativa biologics:** Typically involves specific diagnosis and prior treatment documentation.
• **Mohs micrographic surgery:** Requires documentation of site (cosmetically/functionally sensitive area), tumor type, and conformance with AAD Appropriate Use Criteria.
• **Advanced skin cancer treatments:** Often necessitates detailed pathology reports and adherence to NCCN guidelines.
• **Phototherapy:** PA-relevant when self-administered home phototherapy is prescribed, requiring documentation of prior topical therapy trials.

Common Prior Authorization Denial Reasons in Dermatology

Understanding frequent denial reasons is crucial for optimizing PA workflows. In dermatology, common issues include failure to document step therapy for psoriasis biologics (e.g., prior topical, phototherapy, or methotrexate trials), biosimilar substitution mandates for TNF inhibitors, Mohs AUC mismatches, insufficient documentation of disease severity (missing PASI, EASI, BSA scores), and gaps in pre-biologic screenings like TB and hepatitis. Proactive validation against payer policies and clinical guidelines is essential to mitigate these denials.

Klivira's Solution for Dermatology Prior Authorization

Klivira's platform is engineered to address the specific PA challenges faced by dermatology practices. Our system incorporates AAD-guideline-aware step-therapy logic for psoriasis and atopic dermatitis biologics, provides AUC validation for Mohs surgery, and manages periodic re-authorization workflows for chronic biologic treatments. By automating medical-vs-pharmacy benefit routing and integrating with payer portals, Klivira reduces manual effort and improves approval rates for all PAs, including those for high-volume drugs like Toujeo.

Integrating Klivira for Enhanced PA Workflows

Klivira integrates seamlessly with existing EMR systems, leveraging standards like SMART on FHIR and X12 278 to streamline data exchange. This robust connectivity ensures that all relevant patient information, clinical notes, and payer responses are efficiently managed within a single platform. By automating the submission process and tracking PA statuses, Klivira empowers dermatology practices to reduce administrative overhead and focus more on patient care, whether for complex biologics or high-volume drug authorizations.